MedDataX Logo

Population-based Age-stratified Seroepidemiological Investigation Protocol for Coronavirus 2019 (COVID-19) Infection in the Federation of Bosnia and Herzegovina

NCT ID: NCT05124535

Last Updated: 2021-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1152 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-11-17

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is the second cross-sectional study conducted in the region. In the first cross sectional study, conducted in the winter of 2020, we aimed to estimate the seroprevalence of SARS-CoV-2 IgG antibodies among blood donors in Sarajevo Canton. We also assessed immune durability among seropositive participants after 6 months. In total, of 1015 blood donors aged 18-65 years in Sarajevo Canton between 2 November and 3 December 2020 were recruited and population-weighted seroprevalence in Sarajevo Canton was 19.2% (95% CI: 16.7-21.6%). The aim of this second cross-sectional study is to measure the seroprevalence SARS-CoV-2 antibodies and assess antibody kinetics in the blood donor population after 12 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Seroprevalence Antibody COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Persons aged 18-29

No interventions assigned to this group

Persons aged 30-39

No interventions assigned to this group

Persons aged 40-65

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All individuals identified for recruitment into the investigation, resident of Canton Sarajevo between 18-65 years, irrespective of prior COVID-19 infection.

Exclusion Criteria

* Refusal to give informed consent or to attend follow-up appointments; currently experiencing COVID-19 symptoms or in the last 14 days; and close contact with a confirmed case of COVID-19 within 14 days prior to donation.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

World Health Organization

OTHER

Sponsor Role collaborator

Institute for Public Health of the Federation of Bosnia and Herzegovina

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institute for Transfusion Medicine of the Federation of Bosnia and Herzegovina

Sarajevo, , Bosnia and Herzegovina

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Bosnia and Herzegovina

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Veronica I Sawin, ScM

Role: CONTACT

Phone: +38762022240

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sanjin Musa, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Musa S, Catovic Baralija E, Ivey Sawin V, Nardone A, Palo M, Skocibusic S, Blazevic M, Cilovic Lagarija S, Ahmetovic-Karic G, Ljuca A, Dostovic-Halilovic S, Nedic R, Subissi L, Ibrahim R, Boshevska G, Bergeri I, Pebody R, Vaughan A. Evolution of seroprevalence to SARS-CoV-2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: Cross-sectional and longitudinal studies. Influenza Other Respir Viruses. 2023 Aug 22;17(8):e13182. doi: 10.1111/irv.13182. eCollection 2023 Aug.

Reference Type DERIVED
PMID: 37621919 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

001

Identifier Type: -

Identifier Source: org_study_id